Registry following adults with lymphatic blood cancers across Germany
Records treatment, disease course and patient-reported outcomes in adults with lymphoma or leukemia.
Plain-language title generated from the registry record
Registry title: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Key facts
- Where
- Freiburg im Breisgau, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults with a confirmed non-Hodgkin lymphoma, such as CLL, DLBCL, FL, MCL, MZL or Waldenström's macroglobulinemia, who get systemic therapy.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- A confirmed diagnosis of the respective non-Hodgkin lymphoma.
Main reasons for not taking part
- No systemic therapy for the lymphoid malignancy
- No signed written informed consent, if the patient is alive
Read by machine on 12 November 2026.
Where in Germany
- Praxis für Interdisziplinäre Hämatologie und OnkologieFreiburg im Breisgau, GermanyContact: Martina Jänicke, Dr.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- iOMEDICO AG
- Trial code
- NCT06043011
- Record updated
- 13 July 2026
- Original description
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.Read full original descriptionShow less
Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.
Inclusion: Age ≥ 18 years; Confirmed diagnosis of the respective NHL; If patient is alive: signed written informed consent; For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment; For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.
Exclusion: No systemic therapy for respective lymphoid malignancy.